Google
GTBP — GT BIOPHARMA INC (Healthcare >> Biotechnology)
GTBP FAQ
What is GTBP's P/E ratio?
GT BIOPHARMA INC (GTBP) currently trades at a P/E ratio of 1.90.
What is GTBP's ROE?
GT BIOPHARMA INC reports a Return on Equity (ROE) of -629.74%.
What is GTBP's dividend yield?
GT BIOPHARMA INC offers a dividend yield of 0.00%.
What is GTBP's Deepscope Quality Score?
Deepscope rates GTBP's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GTBP?
Deepscope's AI Timing Score for GTBP is 62 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GTBP belong to?
GT BIOPHARMA INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.44
Price
-0.04
(-8.51%)
Day Change
|
|
|---|
GTBP, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.44 |
| PBV / Sector |
2.08 / 4.63
|
| Earning Per Share | -1.32 |
| PE / Sector |
1.90 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
0.01 / 0.53
GREAT
|
| Average 1M Daily Value |
1.03 M
GREAT
|
| Average 1W Daily Value |
0.83 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:45 |
| Symbol | GTBP |
| Name | GT BIOPHARMA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 36.06 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 15.74 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 315 Montgomery Street, San Francisco, CA, United States, 94104
Phone: 415 919 4040
Website: https://www.gtbiopharma.com
Sector: Healthcare >> Biotechnology
Description: GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
